Uniogen’s cancer diagnostic platform is based on research conducted and published at the University of Turku. Studies show that the concept of glycosylation-specific immunoassays is clearly superior to currently used blood-based markers in cancer diagnosis and monitoring.

See the list of publications here: Cancer diagnostics – Uniogen

In addition, Uniogen owns several patents related to the technology and has performed inhouse research, which has led to the diagnostic product development at Uniogen.